Generic Neupro Availability
Last updated on Apr 10, 2025.
Neupro is a brand name of rotigotine, approved by the FDA in the following formulation(s):
NEUPRO (rotigotine - film, extended release;transdermal)
-
Manufacturer: UCB INC
Approval date: May 9, 2007
Strength(s): 2MG/24HR [RLD], 4MG/24HR [RLD], 6MG/24HR [RLD] -
Manufacturer: UCB INC
Approval date: April 2, 2012
Strength(s): 1MG/24HR [RLD], 3MG/24HR [RLD], 8MG/24HR [RLD]
Is there a generic version of Neupro available?
No. There is currently no therapeutically equivalent version of Neupro available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Neupro. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
Patent 10,130,589
Issued: November 20, 2018
Inventor(s): Wolff; Hans-Michael et al.
Assignee(s): UCB Pharma GmbH (Monheim, DE); LTS Lohmann Therapie-Systeme AG (Andernach, DE)The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.
Patent expiration dates:
- December 22, 2030✓
- December 22, 2030
-
Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
Patent 10,350,174
Issued: July 16, 2019
Inventor(s): Wolff; Hans-Michael et al.
Assignee(s): UCB Pharma GmbH (Monheim, DE); LTS Lohmann Therapie-Systeme AG (Andernach, DE)The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.
Patent expiration dates:
- December 22, 2030✓
- December 22, 2030
-
Transdermal delivery system for the administration of rotigotine
Patent 8,246,979
Issued: August 21, 2012
Inventor(s): Schacht Dietrich Wilhelm & Hannay Mike & Wolff Hans-Michael
Assignee(s): UCB Pharma GmbHAn improved transdermal delivery system (TDS) comprises a self-adhesive matrix comprising a solid or semi-solid semi-permeable polymer which contains rotigotine in its free base form as a multitude of microreservoirs within the matrix. The self-adhesive matrix is highly permeable to the free base of rotigotine and is impermeable to the protonated form of rotigotine.
Patent expiration dates:
- September 1, 2027✓✓
- September 1, 2027✓✓
- September 1, 2027
-
Transdermal delivery system
Patent 8,246,980
Issued: August 21, 2012
Inventor(s): Schacht Dietrich Wilhelm & Hannay Mike & Wolff Hans-Michael
Assignee(s): UCB Pharma GmbHAn improved transdermal delivery system (TDS) comprises a self-adhesive matrix comprising a solid or semi-solid semi-permeable polymer which contains an amine-functional drug in its free base form as a multitude of microreservoirs within the matrix. The self-adhesive matrix is highly permeable to the free base of the amine-functional drug and is impermeable to the protonated form of the amine-functional drug.
Patent expiration dates:
- November 27, 2025✓
- November 27, 2025
-
Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
Patent 9,925,150
Issued: March 27, 2018
Inventor(s): Wolff; Hans-Michael et al.
Assignee(s): LTS Lohmann Therapie-Systeme AG (Andernach, DE); UCB Pharma GmbH (Monheim, DE)The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.
Patent expiration dates:
- March 1, 2032✓
- March 1, 2032
More about Neupro (rotigotine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (73)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: dopaminergic antiparkinsonism agents
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
